MapLight’s Board Overhaul Signals a Pivot from Science to Strategy

SAN FRANCISCO, CA – June 24, 2026 – MapLight Therapeutics, Inc. (Nasdaq: MPLT) has executed a significant and telling evolution of its leadership, appointing two biopharmaceutical heavyweights with formidable track records in corporate acquisitions to its Board of Directors. The addition of Martin Babler and Troy Cox, announced following the company's annual stockholder meeting, is far more than a routine governance update. It represents a deliberate strategic pivot for the clinical-stage company, signaling a transition from its foundational scientific roots toward a future focused on high-stakes clinical execution, commercial readiness, and strategic value creation.

The appointments coincide with the departure of co-founding scientist Robert Malenka, M.D., Ph.D., and early-stage venture investor Jim Trenkle, Ph.D. While the company expressed gratitude for their service, the change in personnel speaks volumes. By bringing in leaders who have successfully navigated two of the last decade's major biopharma acquisitions, MapLight is arming itself with the expertise needed to mature from a promising CNS innovator into a formidable market player.

“We are grateful to Rob and Jim for their years of leadership and service to MapLight, and we are pleased to welcome Martin and Troy to the Board. Both bring substantial strategic, operational and governance experience,” said Chris Kroeger, co-Founder and Chief Executive Officer of the Company. “Their proven leadership across biotechnology will support MapLight as we continue executing on our strategy to develop meaningful therapies for patients with CNS disorders.”

A Deliberate Shift from Foundation to Execution

The departure of Dr. Malenka and Dr. Trenkle marks the end of an era for MapLight. Dr. Malenka, a world-renowned neuroscientist from Stanford University, was instrumental in establishing the company's scientific bedrock. His pioneering research into synaptic plasticity and neural circuits provided the intellectual foundation for MapLight's proprietary discovery platform. Similarly, Dr. Trenkle, representing Novo Holdings, was pivotal in securing the crucial funding—including a $225 million Series C in 2023 and a massive $372.5 million Series D in 2025—that propelled the company through its early clinical stages and its late 2025 IPO.

Their contributions represent the essential first act of any successful biotech: building a novel scientific platform and securing the capital to validate it. However, as a company's lead assets advance into late-stage trials, the required skill set evolves. The challenges shift from pure science to the complex domains of clinical operations, regulatory navigation, corporate governance, and ultimately, commercialization and strategic transactions. The board appointments reflect a clear-eyed recognition of this inflection point. By characterizing the move as an "orderly refresh," MapLight’s leadership is signaling that this is a planned and necessary phase of its corporate maturation, replacing foundational expertise with the battle-hardened experience needed for the next chapter.

The M&A Playbook: A New Era of Leadership

The new directors are not just experienced executives; they are architects of significant shareholder value. Martin Babler led Principia Biopharma as CEO from 2011 until its acquisition by Sanofi for a staggering $3.68 billion in 2020. That deal was largely driven by Principia’s portfolio of BTK inhibitors, including a brain-penetrant asset for CNS diseases—an area of direct relevance to MapLight’s mission. Babler’s experience demonstrates a clear ability to develop a promising pipeline and guide a company to a highly successful strategic exit.

Troy Cox brings a similarly impressive M&A pedigree. As CEO of Foundation Medicine from 2017 to 2019, he presided over its acquisition by Roche for $5.3 billion. This transaction solidified Roche’s leadership in oncology diagnostics and personalized medicine, and Cox was at the helm of the integration. His background is a masterclass in positioning a company with a unique technological platform for acquisition by a pharmaceutical giant. The combined experience of Babler and Cox provides MapLight with an invaluable internal playbook on how to engage with big pharma, structure potential partnerships, and maximize value, whether through a strategic sale or robust independent growth.

Sharpening Focus on a Challenging CNS Pipeline

Beyond their M&A acumen, the new appointees bring critical operational expertise directly applicable to MapLight's pipeline. The development of drugs for central nervous system disorders is notoriously difficult, plagued by high failure rates, the challenge of crossing the blood-brain barrier, and the complexity of trial design. This is precisely where seasoned leadership can make a difference.

Troy Cox’s tenure as President of CNS Operations at UCB BioPharmaceuticals is particularly noteworthy. This hands-on experience in the very sector MapLight aims to disrupt provides the board with deep, practical insights into the unique hurdles of CNS drug development and commercialization. This expertise will be invaluable as MapLight prepares for key data readouts for its lead candidate, ML-007C-MA. Topline results from the Phase 2 ZEPHYR trial in schizophrenia are expected in the second half of 2026, with data from the VISTA trial in Alzheimer's disease psychosis to follow in 2027.

These upcoming milestones represent major catalysts for the company, and having leaders like Cox and Babler, who have overseen numerous clinical programs, will be critical in interpreting results, planning next steps, and communicating the story to investors. Their presence bolsters the governance framework, ensuring rigorous oversight as the company navigates the high-pressure environment of late-stage clinical development.

Navigating Market Realities and Investor Expectations

The board changes are also a strategic response to market dynamics. While MapLight enjoys a strong balance sheet with more cash than debt following its recent IPO and financing rounds, it is also a pre-revenue company with accelerating cash burn. Analyst sentiment reflects this duality; while most maintain 'Buy' ratings, Craig-Hallum recently trimmed its price target from $43.00 to $40.00, a sign of the cautious optimism that surrounds clinical-stage biotechs.

By installing directors with a proven ability to deliver returns, MapLight is sending a powerful message to investors. It demonstrates a commitment to disciplined capital allocation and a focus on creating tangible value from its scientific platform. As the company approaches pivotal data readouts, the market will be looking for signs of experienced stewardship. The addition of Babler and Cox provides exactly that, enhancing investor confidence that the company is not only pioneering new science but is also being guided by leaders who know how to win in the competitive biopharmaceutical arena.